EUCTR2020-004741-37-Outside-EU/EEA
进行中（未招募）
1 期
A Phase I/II, observer-blind, randomised, controlled study to assess the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine when administered to healthy adults (Phase I) and to healthy adolescents and adults (Phase II)
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y)
- 发起方
- GlaxoSmithKline Biologicals
- 状态
- 进行中（未招募）
- 最后更新
- 4年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •All inclusion criteria are applicable for both study phases, except where specified otherwise.
- •Participants and/or participants’ parent(s)/Legally Acceptable Representative(s) (LAR) who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g. completion of the eDiaries, return for follow\-up visits).
- •Written or witnessed/thumb printed informed consent obtained from the participant or /parent(s)/LAR(s) of the participant prior to performance of any study specific procedure.
- •Written informed assent obtained from the participant (if applicable) prior to performing any study specific procedure.
- •Phase I and Phase II (Sourcing) only: A male or female between, and including, 18 and 40 years of age (i.e. 40 years \+ 364 days) at the time of the first study intervention administration.
- •Phase II (Formulation and Schedule\-finding) only: A male or female between, and including, 10 and 25 years of age (i.e. 25 years \+ 364 days) at the time of the first study intervention administration.
- •Participants who are either unvaccinated with MenACWY vaccine or have received a single previous dose of MenACWY vaccine can participate in the study, if they have received it at least 4 years prior to informed consent and assent as applicable (with the exception of meningococcal C vaccination, if the last dose of MenC was received at \= 24 months of age).
- •Healthy participants as established by medical history and clinical examination before entering into the study.
- •Female participants of non\-childbearing potential may be enrolled in the study. Non\-childbearing potential is defined as pre\-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post\-menopause.
- •Female participants of childbearing potential may be enrolled in the study, if the participant:
排除标准
- •Medical conditions
- •Current or previous, confirmed or suspected disease caused by N. meningitidis.
- •Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection within 60 days of enrolment.
- •Progressive, unstable or uncontrolled clinical conditions.
- •Clinical conditions representing a contraindication to intramuscular vaccination and blood draws.
- •Are obese at enrolment (e.g. for participants from 20 years of age a body mass index (BMI) \= 30 kg/m2, for participants up to 19 years of age a BMI \= 95th percentile for age and gender or as applicable per country recommendations).
- •Any neuroinflammatory (including but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), congenital neurological conditions, encephalopathies, seizures (including all subtypes such as: absence seizures, generalised tonic\-clonic seizures, partial complex seizures, partial simple seizures). History of febrile convulsions should not lead to exclusion.
- •History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions.
- •Hypersensitivity, including allergy, to any component of vaccines, including diphtheria toxoid (CRM197\) and latex medicinal products or medical equipment whose use is foreseen in this study.
- •Abnormal function or modification of the immune system resulting from:
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
A study to evaluate the safety, reactogenicity nad immunogenicity of the GSK investigational vaccine GSK3003891A in healthy pregnant women and infants born to vaccinated mothersEUCTR2016-002733-30-FIGlaxoSmithKline Biologicals500
进行中（未招募）
1 期
A study to evaluate the safety, reactogenicity nad immunogenicity of the GSK investigational vaccine GSK3003891A in healthy pregnant women and infants born to vaccinated mothersEUCTR2016-002733-30-GBGlaxoSmithKline Biologicals500
进行中（未招募）
1 期
A study to evaluate the safety, reactogenicity nad immunogenicity of the GSK investigational vaccine GSK3003891A in healthy pregnant women and infants born to vaccinated mothersHealthy pregnant women (Respiratory Syncytial Virus)MedDRA version: 19.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2016-002733-30-ESGlaxoSmithKline S.A500
进行中（未招募）
不适用
A phase I/II, observer-blind, randomized, controlled study to assess the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy male subjects aged 10-18 years. - HPV-011In female subjects from 10 years of age onwards for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including ASC-US, cervical intraepithelial neoplasia (CIN) and pre-cancerous lesions caused by oncogenic human papillomaviruses (HPV). In male subjects from 10 years of age onwards for the prevention of transmission of human papillomaviruses (HPV) causing persistent infections and related clinical outcomes.EUCTR2005-005943-24-FIGlaxoSmithKline Biologicals270
进行中（未招募）
1 期
A study to evaluate safety, reactogenicity, and immune response of GVGH iNTS TCV vaccine against invasive nontyphoidal Salmonella and Typhoid FeverHealthy volunteers (prevention of invasive nontyphoidal Salmonella disease and typhoid fever)Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2021-005178-25-BEGlaxoSmithKline Biologicals SA155